Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Pharmacology and Therapeutics

• Publication date

  2016-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.pharmthera.2016.09.007PMID 27598860
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rosiglitazone Promotes AQP2 Plasma Membrane Expression In Renal Cells Via a Ca2+-Dependent/cAMP-Independent Mechanism

  2015cited by this paper
• Was there really any evidence that rosiglitazone increased the risk of myocardial infarction or death from cardiovascular causes?

  2015cited by this paper
• Comparision of secretagogue effects of rosiglitazone and telmisartan on ANP secretion in rats.

  2014influential reference
• PPARγ-Induced Stimulation of Amiloride-Sensitive Sodium Current in Renal Collecting Duct Principal Cells is Serum and Insulin Dependent

  2014cited by this paper
• Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits.

  2014cited by this paper
• PPARγ Agonist-Induced Fluid Retention Depends on αENaC Expression in Connecting Tubules

  2014influential reference
• Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice.

  2014influential reference
• Rosiglitazone Induces Cardiotoxicity by Accelerated Apoptosis

  2014cited by this paper
• Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub‐study of the DREAM trial

  2014cited by this paper
• Rosiglitazone inhibits expression and secretion of PEDF in adipose tissue and liver of male SD rats via a PPAR-γ independent mechanism.

  2014cited by this paper
• Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor γ-independent mitochondrial oxidative stress in mouse hearts.

  2014cited by this paper
• A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone

  2014influential reference
• Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.

  2014cited by this paper
• Review of the quality of observational studies of the association between rosiglitazone and acute myocardial infarction.

  2014cited by this paper
• Rosiglitazone Did Not Induce Acute Kidney Injury in Normocholesterolemic Rats Despite Reduction in Glomerular Filtration Rate

  2014cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cited by this paper
• Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular Mechanisms

  2013influential reference
• Rosiglitazone: a case of regulatory hubris

  2013influential reference
• Impact of thiazolidinediones on macular thickness and volume in diabetic eyes.

  2013cited by this paper
• SUMOylation of PPARγ by Rosiglitazone Prevents LPS-Induced NCoR Degradation Mediating Down Regulation of Chemokines Expression in Renal Proximal Tubular Cells

  2013cited by this paper
• Metabonomic investigation on the protective effects of rosiglitazone and caloric restriction for renal senescence in a rat model

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2013cited by this paper
• Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes.

  2013cited by this paper
• Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?

  2013influential reference
• Role of the EGF receptor in PPARγ-mediated sodium and water transport in human proximal tubule cells

  2013influential reference
• Peroxisome Proliferator-Activated Receptor γ Agonists Attenuate Hyperglycaemia-Induced Hyaluronan Secretion in Vascular Smooth Muscle Cells by Inhibiting PKCβ2

  2013cited by this paper
• Rosiglitazone alleviates injury in rats with adenine‑induced chronic kidney disease.

  2013cited by this paper
• US regulators relax restrictions on rosiglitazone

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones.

  2013influential reference
• Peroxisome Proliferator–Activated Receptor-&ggr; Activation Prevents Sepsis-Related Cardiac Dysfunction and Mortality In Mice

  2013cited by this paper
• Combination of a peroxisome proliferator‐activated receptor‐gamma agonist and an angiotensin II receptor blocker attenuates myocardial fibrosis and dysfunction in type 2 diabetic rats

  2013cited by this paper
• Distinct mechanisms for globular adiponectin that integrate vascular and metabolic actions of insulin to help maintain coordinated cardiovascular and glucose homeostasis.

  2013cited by this paper
• Pioglitazone ameliorates systolic and diastolic cardiac dysfunction in rat model of angiotensin II-induced hypertension.

  2013influential reference
• Rosiglitazone and cardiovascular outcomes: is there a clear answer?

  2013influential reference
• Research Advances in Heart Failure: A Compendium

  2013cited by this paper
• Expansion: Role of Dysregulation of Renal Water Transporters

  2013influential reference
• A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes.

  2013cited by this paper
• Cardiac Adaptation to Volume Overload

  2013cited by this paper
• Results of a reevaluation of cardiovascular outcomes in the RECORD trial.

  2013cited by this paper
• Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.

  2013cited by this paper
• Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin and Angiotensin Converting Enzyme 2 Excretion

  2013cited by this paper
• PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury

  2013cited by this paper
• PPAR-γ activation by rosiglitazone suppresses angiotensin II-mediated proliferation and phenotypictransition in cardiac fibroblasts via inhibition of activation of activator protein 1.

  2013cited by this paper
• Epidemiology of Heart Failure

  2013cited by this paper
• Combined Effects of PPARγ Agonists and Epidermal Growth Factor Receptor Inhibitors in Human Proximal Tubule Cells

  2013cited by this paper
• PPARγ Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice

  2013cited by this paper
• Peroxisome Proliferator-Activated Receptor-&ggr; Regulates Inflammation and Renin-Angiotensin System Activity in the Hypothalamic Paraventricular Nucleus and Ameliorates Peripheral Manifestations of Heart Failure

  2012influential reference
• Effects of PPARγ ligands on vascular tone.

  2012cited by this paper
• GQ-16, a Novel Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand, Promotes Insulin Sensitization without Weight Gain

  2012cited by this paper
• Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders

  2012cited by this paper
• Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure.

  2012cited by this paper
• Thiazolidinedione‐dependent activation of sphingosine kinase 1 causes an anti‐fibrotic effect in renal mesangial cells

  2012cited by this paper
• Rosiglitazone Causes Endothelial Dysfunction in Humans

  2012cited by this paper
• Glitazones in chronic kidney disease: potential and concerns.

  2012cited by this paper
• Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial

  2012cited by this paper
• Protective effects of PPARγ agonist in acute nephrotic syndrome.

  2012cited by this paper
• Rosiglitazone Affects Nitric Oxide Synthases and Improves Renal Outcome in a Rat Model of Severe Ischemia/Reperfusion Injury

  2012cited by this paper
• Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.

  2012cited by this paper
• Determinants of evolving metabolic and cardiovascular benefit/risk profiles of rosiglitazone therapy during the natural history of diabetes: molecular mechanisms in the context of integrated pathophysiology.

  2012influential reference
• Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin.

  2012influential reference
• Improved insulin sensitivity after treatment with PPAR&ggr; and PPAR&agr; ligands is mediated by genetically modulated transcripts

  2012cited by this paper
• Chemical Proteomics‐Based Analysis of Off‐target Binding Profiles for Rosiglitazone and Pioglitazone: Clues for Assessing Potential of Cardiotoxicity

  2012cited by this paper
• Anti‐proliferative effect of rosiglitazone on angiotensin II‐induced vascular smooth muscle cell proliferation is mediated by the mTOR pathway

  2012cited by this paper
• Peroxisome proliferator-activated receptor γ agonist rosiglitazone increases expression of very low density lipoprotein receptor gene in adipocytes

  2012cited by this paper
• Effects of PPARs Agonists on Cardiac Metabolism in Littermate and Cardiomyocyte-Specific PPAR-γ –Knockout (CM-PGKO) Mice

  2012cited by this paper
• Neurohumoral stimulation.

  2012cited by this paper
• Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

  2012influential reference
• Reduction of renal lipid content and proteinuria by a PPAR-γ agonist in a rat model of angiotensin II-induced hypertension.

  2012cited by this paper
• The effects of rosiglitazone on myocardial triglyceride content in patients with type 2 diabetes: A randomised, placebo-controlled trial

  2012cited by this paper
• Peroxisome Proliferator–Activated Receptor-&ggr; Activation Induces 11&bgr;-Hydroxysteroid Dehydrogenase Type 1 Activity in Human Alternative Macrophages

  2012cited by this paper
• High-dose rosiglitazone is pro-atherogenic in cholesterol-fed rabbits.

  2012cited by this paper
• Rosiglitazone preserves pulmonary vascular function in lambs with increased pulmonary blood flow

  2012cited by this paper
• Expression Profile of Nuclear Receptors along Male Mouse Nephron Segments Reveals a Link between ERRβ and Thick Ascending Limb Function

  2012cited by this paper
• 2-Hydroxy-4'-Methoxychalcone Inhibits Proliferation and Inflammation of Human Aortic Smooth Muscle Cells by Increasing the Expression of Peroxisome Proliferator–Activated Receptor Gamma

  2012cited by this paper
• Antidiabetic actions of a non–agonist PPARγ ligand blocking Cdk5–mediated phosphorylation

  2012cited by this paper
• Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes.

  2012cited by this paper
• Pleiotropic Effects of Glitazones: A Double Edge Sword?

  2011cited by this paper
• Endothelial Surface N-Glycans Mediate Monocyte Adhesion and Are Targets for Anti-inflammatory Effects of Peroxisome Proliferator-activated Receptor γ Ligands*

  2011cited by this paper
• Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.

  2011cited by this paper
• Rosiglitazone Restores Endothelial Dysfunction in a Rat Model of Metabolic Syndrome through PPARγ- and PPARδ-Dependent Phosphorylation of Akt and eNOS

  2011cited by this paper
• Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome

  2011cited by this paper
• Thiazolidinediones enhance sodium-coupled bicarbonate absorption from renal proximal tubules via PPARγ-dependent nongenomic signaling.

  2011influential reference
• Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production.

  2011cited by this paper
• Effects of Chronic Rosiglitazone Treatment on Renal Handling of Salt and Water in Rats With Volume-Overload Congestive Heart Failure

  2011influential reference
• PPARγ attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells.

  2011cited by this paper
• Preserved Response to Diuretics in Rosiglitazone‐Treated Subjects With Insulin Resistance: A Randomized Double‐Blind Placebo‐Controlled Crossover Study

  2011influential reference
• Challenges in Drug Discovery for Thiazolidinedione Substitute.

  2011cited by this paper
• Transforming growth factor-&bgr; inhibits myocardial PPAR&ggr; expression in pressure overload-induced cardiac fibrosis and remodeling in mice

  2011cited by this paper
• Increased renal ENaC subunits and sodium retention in rats with chronic heart failure.

  2011cited by this paper
• Rosiglitazone, a PPAR-γ agonist, inhibits VEGF secretion by peripheral blood mononuclear cells and ROS production by human leukocytes

  2011cited by this paper
• Genetic predisposition and nongenetic risk factors of thiazolidinedione-related edema in patients with type 2 diabetes

  2011cited by this paper
• Opposing actions of rosiglitazone and resveratrol on mineralization in human vascular smooth muscle cells.

  2011cited by this paper
• Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone

  2011cited by this paper
• Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel‐group study in patients with type 2 diabetes on stable insulin therapy

  2011cited by this paper
• Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro

  2011cited by this paper
• Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline

  2011cited by this paper
• Assessment of cardiac structure and function in patients without and with peripheral oedema during rosiglitazone treatment

  2011influential reference
• Role of pioglitazone in the prevention of restenosis and need for revascularization after bare-metal stent implantation: a meta-analysis.

  2011influential reference
• Anti-Diabetic Actions of a Non-Agonist PPARγ Ligand Blocking Cdk5-Mediated Phosphorylation

  2011cited by this paper

• Synthesis, in silico studies and biological evaluation of novel thiazolidinone[5,4-d] isoxazole derivatives as antidiabetic agents

  2025cites this paper
• Dehydrozaluzanin C inhibits colon cancer cell proliferation, apoptosis and cycle arrest through peroxisome proliferator-activated receptor γ (PPARγ) activation

  2025cites this paper
• Recent Advances in Promoting Bone Regeneration in Type 2 Diabetes Using Drug Delivery Vehicles and Vehicle‐Free Therapeutics

  2025cites this paper
• Enhanced Outcomes in Type 2 Diabetes Patients with Acute Kidney Disease Through Thiazolidinedione.

  2024cites this paper
• Regulation of transcription factor function by purinergic signalling in cardiovascular diseases

  2024cites this paper
• Impaired Remodeling of White Adipose Tissue in Obesity and Aging: From Defective Adipogenesis to Adipose Organ Dysfunction

  2024cites this paper
• Synthesis, molecular docking, and in vivo antidiabetic evaluation of new benzylidene-2,4-thiazolidinediones as partial PPAR-γ agonists

  2023cites this paper
• Gene Expression Analyses in Models of Rosiglitazone-Induced Physiological and Pathological Mineralization Identify Novel Targets to Improve Bone and Vascular Health

  2023cites this paper
• Dietary regulation of peroxisome proliferator-activated receptors in metabolic syndrome.

  2023cites this paper
• Jinlida granules combined with metformin improved the standard-reaching rate of blood glucose and clinical symptoms of patients with type 2 diabetes: secondary analysis of a randomized controlled trial

  2023cites this paper
• Dietary carbohydrates: Pathogenesis and potential therapeutic targets to obesity‐associated metabolic syndrome

  2022cites this paper
• Combined Cardioprotective and Adipocyte Browning Effects Promoted by the Eutomer of Dual sEH/PPARγ Modulator.

  2021cites this paper
• Ectopic Overexpression of PPARγ2 in the Heart Determines Differences in Hypertrophic Cardiomyopathy After Treatment With Different Thiazolidinediones in a Mouse Model of Diabetes

  2021cites this paper
• Heart failure in patients with diabetic cardiomyopathy: modern methods of treatment

  2020cites this paper
• Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver

  2020cites this paper
• Thiazolidinediones: the Forgotten Diabetes Medications

  2019cites this paper
• Rosiglitazone treatment restores renal responsiveness to atrial natriuretic peptide in rats with congestive heart failure

  2019cites this paper
• Rosiglitazone promotes ENaC-mediated alveolar fluid clearance in acute lung injury through the PPARγ/SGK1 signaling pathway

  2019cites this paper
• Targeting the Canonical WNT/β-Catenin Pathway in Cancer Treatment Using Non-Steroidal Anti-Inflammatory Drugs

  2019cites this paper
• TRPV1 Antagonists as Novel Anti-Diabetic Agents: Regulation of Oral Glucose Tolerance and Insulin Secretion Through Reduction of Low-Grade Inflammation?

  2019cites this paper
• A Systematic Review On Synthetic Drugs And Phytopharmaceuticals Used To Manage Diabetes.

  2019cites this paper
• PPARγ agonists: potential treatment for autism spectrum disorder by inhibiting the canonical WNT/β-catenin pathway

  2018influential citation
• Herzinsuffizienz bei Diabetes

  2018cites this paper
• Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension

  2018cites this paper
• Minireview of Adverse Effects of Some Drugs Used in Diabetes Mellitus

  2018cites this paper
• First total synthesis of cyclic pentadepsipeptides Hikiamides A–C

  2018cites this paper
• Evidence for the Prevention of Type 2 Diabetes Mellitus

  2018cites this paper
• Trans‐repression of NFκB pathway mediated by PPARγ improves vascular endothelium insulin resistance

  2018cites this paper
• Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology

  2018cites this paper
• TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?

  2017cites this paper
• Yixinshu ameliorates hippocampus abnormality induced by heart failure via the PPARγ signaling pathway

  2017cites this paper
• Vignette therapeutique de l'etudiant. Quel medicament antidiabetique choisir chez un patient diabetique de type 2 avec insuffisance cardiaque ?

  2017cites this paper
• [The safety of anti-diabetic drugs in heart failure].

  2017cites this paper
• Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors

  2017cites this paper